TY  - BOOK
AU  - Ozcan Basaran
AU  -  Murat Biteker 
TI  - Anticoagulation Therapy
SN  - 9789535126669 
U1  - 615 
PY  - 2016///
CY  - New York
PB  - BoD – Books on Demand, 
KW  -  
N1  - Contents:

Comparative Biology of the Resistance to Vitamin
	
	
The Risk Factors of Thrombogenic Thrombophilia and
	
	
Management of Anticoagulation Around Cardiac Implantable
	
	
Prothrombin Complex Concentrate a General Antidote for Oral
	
	
NonVitamin K Antagonist Oral Anticoagulants in Atrial
	
	
NonVitamin K Antagonist Oral Anticoagulants Clinical Use
	
	

N2  - The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists
ER  -